Mereo Stock Analysis


USD 0.86  0.02  2.27%   

The big decline in price over the last few months for Mereo Biopharma Groupmay encourage institutional investors to take a closer look at the firm as it is trading at a share price of 0.86 on 290,450 in trading volume. The company management teams failed to add value to investors and position the firm supply of money to exploit market volatility in September. However, diversifying your holdings with Mereo Biopharma or similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 5.48. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Mereo Biopharma Group partners.
Additionally, see Correlation Analysis.
The Mereo Biopharma stock analysis report makes it easy to digest most publicly released information about Mereo Biopharma and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Mereo Stock analysis module also helps to analyze the Mereo Biopharma price relationship with some important fundamental indicators such as market cap and management efficiency.

Mereo Stock Analysis Notes

About 80.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.48. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Mereo Biopharma Group recorded a loss per share of 3.34. The entity had not issued any dividends in recent years. Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom. Mereo Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 49 people. To find out more about Mereo Biopharma Group contact Denise ScotsKnight at 44 33 3023 7300 or learn more at

Mereo Biopharma Group Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Mereo Biopharma's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Mereo Biopharma Group or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Mereo Biopharma generated a negative expected return over the last 90 days
Mereo Biopharma has high historical volatility and very poor performance
Mereo Biopharma has some characteristics of a very speculative penny stock
Mereo Biopharma has high likelihood to experience some financial distress in the next 2 years
Mereo Biopharma Group currently holds about 94.3 M in cash with (5.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.81.
Over 80.0% of the company shares are owned by institutional investors
Latest headline from Mereo BioPharma Offered to Settle Proxy Contest with Rubric Capital Management by Putting Rubric Principal and Second New Director on the Board - Yahoo Finance UK

Mereo Biopharma Group Upcoming and Recent Events

Earnings reports are used by Mereo Biopharma to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Mereo Biopharma previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report30th of March 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End30th of March 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Mereo Biopharma SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Mereo Biopharma prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Mereo Biopharma investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Mereo Biopharma Group specific information freely available to individual and institutional investors to make a timely investment decision.
12th of September 2022
Other Events
31st of August 2022
Other Events
23rd of August 2022
Unclassified Corporate Event
22nd of August 2022
Other Events
5th of July 2022
Other Events
14th of June 2022
Unclassified Corporate Event
9th of June 2022
Unclassified Corporate Event
2nd of June 2022
Other Events

Mereo Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Mereo Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Mereo Biopharma Group backward and forwards among themselves. Mereo Biopharma's institutional investor refers to the entity that pools money to purchase Mereo Biopharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Rubric Capital Management LpCommon Shares16.8 M18.8 M
Point72 Asset Management LpCommon Shares10 M11.2 M
Orbimed Advisors LlcCommon Shares9.7 M10.9 M
Suvretta Capital Management LlcCommon Shares9.1 M10.2 M
Rock Springs Capital Management LpCommon Shares6.2 MM
Clearline Capital LpCommon Shares3.1 M3.4 M
Citadel Advisors LlcCommon Shares2.8 M3.1 M
Note, although Mereo Biopharma's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Mereo Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 93.78 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Mereo Biopharma's market, we take the total number of its shares issued and multiply it by Mereo Biopharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Mereo Profitablity

Mereo Biopharma's profitability indicators refer to fundamental financial ratios that showcase Mereo Biopharma's ability to generate income relative to its revenue or operating costs. If, let's say, Mereo Biopharma is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Mereo Biopharma's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Mereo Biopharma's profitability requires more research than a typical breakdown of Mereo Biopharma's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of 34.9 %, which can signify that it executes well on its competitive strategies and has good control over its expenditures. This is very large. Similarly, it shows Operating Margin (OM) of (57.42) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.57.

Management Efficiency

The entity has return on total asset (ROA) of (13.82) % which means that it has lost $13.82 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 34.85 %, meaning that it created $34.85 on every $100 dollars invested by stockholders. Mereo Biopharma management efficiency ratios could be used to measure how well mereo biopharma group manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 3rd of October, Mereo Biopharma secures the mean deviation of 4.51, and Risk Adjusted Performance of (0.08). In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Mereo Biopharma Group, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to analyze and collect data for nineteen technical drivers for Mereo Biopharma, which can be compared to its peers in the industry. Please verify Mereo Biopharma Group variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Mereo Biopharma Group is priced some-what accurately, providing market reflects its recent price of 0.86 per share. Given that Mereo Biopharma Group is a hitting penny stock territory we strongly suggest to closely look at its total risk alpha.

Mereo Biopharma Group Price Movement Analysis

Start Value
Offset on Reverse
AF Init Long
AF Long
AF Max Long
AF Init Short
AF Short
AF Max Short
Execute Study
The output start index for this execution was one with a total number of output elements of sixty. The Extended Parabolic SAR indicator is used to determine the direction of Mereo Biopharma's momentum and the point in time when it has higher than normal probability of directional change. It has more input parameters than standard Parabolic SAR indicator.

Mereo Biopharma Technical and Predictive Indicators

Mereo Biopharma Forecast Models

Mereo Biopharma time-series forecasting models is one of many Mereo Biopharma's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Mereo Biopharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Mereo Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Mereo Biopharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Mereo shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Mereo Biopharma. By using and applying Mereo Stock analysis, traders can create a robust methodology for identifying Mereo entry and exit points for their positions.
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom. Mereo Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 49 people.

Current Mereo Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Mereo analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Mereo analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
Mereo Biopharma Group current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Mereo analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Mereo stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Mereo Biopharma Group, talking to its executives and customers, or listening to Mereo conference calls.
Mereo Analyst Advice Details

Mereo Stock Analysis Indicators

Mereo Biopharma Group stock analysis indicators help investors evaluate how Mereo Biopharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Mereo Biopharma shares will generate the highest return on investment. By understating and applying Mereo Biopharma stock analysis, traders can identify Mereo Biopharma position entry and exit signals to maximize returns.
Quick Ratio7.66
Fifty Two Week Low0.3010
Shares Short Prior Month3.56M
Average Daily Volume Last 10 Day439.48k
Average Daily Volume In Three Month1.39M
Shares Percent Shares Out4.45%
Gross Margins50.89%
Forward Price Earnings-0.02
Float Shares50.03M
Fifty Two Week High2.5900
Enterprise Value To Ebitda-3.05
Fifty Day Average1.1549
Two Hundred Day Average1.1330
Enterprise Value To Revenue1.75
Additionally, see Correlation Analysis. Note that the Mereo Biopharma Group information on this page should be used as a complementary analysis to other Mereo Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Complementary Tools for Mereo Stock analysis

When running Mereo Biopharma Group price analysis, check to measure Mereo Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mereo Biopharma is operating at the current time. Most of Mereo Biopharma's value examination focuses on studying past and present price action to predict the probability of Mereo Biopharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Mereo Biopharma's price. Additionally, you may evaluate how the addition of Mereo Biopharma to your portfolios can decrease your overall portfolio volatility.
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Is Mereo Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mereo Biopharma. If investors know Mereo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mereo Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Mereo Biopharma Group is measured differently than its book value, which is the value of Mereo that is recorded on the company's balance sheet. Investors also form their own opinion of Mereo Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Mereo Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mereo Biopharma's market value can be influenced by many factors that don't directly affect Mereo Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mereo Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Mereo Biopharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mereo Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.